Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566813 | 1.00 | ADRB2 (0.60) | ADRB2ADRB1 | |
| SCHEMBL2578225 | 1.00 | ADRB2 (0.60) | ADRB2ADRB1 | |
| SCHEMBL2564506 | 0.90 | ADRB2 (0.54) | ADRB2ADRB1 | |
| SCHEMBL2568093 | 0.89 | ADRB2 (0.48) | ADRB2ADRB1 | |
| SCHEMBL2568091 | 0.89 | ADRB2 (0.48) | ADRB2ADRB1 | |
| SCHEMBL2563829 | 0.85 | ADRB2 (0.56) | ADRB2ADRB1 | |
| SCHEMBL2563823 | 0.85 | ADRB2 (0.56) | ADRB2ADRB1 | |
| SCHEMBL2565756 | 0.85 | ADRB2 (0.56) | ADRB2ADRB1 | |
| SCHEMBL2560219 | 0.83 | ADRB2 (0.53) | ADRB2ADRB1 | |
| SCHEMBL2560223 | 0.83 | ADRB2 (0.53) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013183-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-11-02 | — | — | EP | claimed |
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-03-26 | — | — | US | claimed |
| EP-2013183-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2009-01-14 | — | — | EP | claimed |
| WO-2007124898-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS, ALMIRALL S.A. (ES) | 2007-11-08 | — | — | WO | claimed |
| EP-2013183-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-11-02 | — | — | EP | disclosed |
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-03-26 | — | — | US | disclosed |
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-03-26 | — | — | US | disclosed |
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-03-26 | — | — | US | disclosed |
| EP-2013183-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124898-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS, ALMIRALL S.A. (ES) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007124898-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS, ALMIRALL S.A. (ES) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.